Gevo raises $107 million in its IPO as synbio stays in the spotlight

February 10, 2011 | Analyst Insight

Earlier this week, isobutanol producer Gevo raised $107 million in its initial public offering (IPO). The synthetic biology company sold approximately 7.1 million shares at $15 apiece, with shares trading as...

Login to View This Research

Already a Lux Client?

Sign In

Not a Lux Client?

Talk to Lux Research now and learn the benefits of becoming a member.

Lux Research

  • Helps clients find new business opportunities from emerging technologies in the physical and life sciences
  • Offers ongoing technology and market intelligence, as well as market data and consulting services
  • Now serves over 250 clients on six continents – multinational corporations, investors, governments, and SMEs
  • Has a Global reach, with offices in Boston, New York, Amsterdam, Singapore, Shanghai, and Tokyo
  • Combines deep technical expertise with business analysis to support strategic decisions

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 (0) 20-3460840

For APAC (Singapore)
+65 6592-6978